Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesInfectious DiseaseAetna HIV Testing Coverage Policy Update | OpenPay…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0542

    HIV Testing

    Customize your policy alerts

    Sign up for Aetna Policy 0542 alerts

    Get alerted when Policy 0542 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical policy describing medical necessity, allowable tests, coding, and limitations for HIV screening and diagnostic testing; applies to Aetna-covered members and laboratories performing HIV tests.

    Policy Summary
    PayerAetna
    PolicyHIV Testing
    Policy CodePolicy 0542
    Change TypeNo material change
    Effective DateN/A
    Last ReviewAug 4, 2023
    Next Review DateN/A
    Key ActionBegin HIV testing with an FDA-approved antigen/antibody combination immunoassay and follow with differentiation immunoassay and HIV-1 NAT as indicated.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    13-64CDC screening age range
    >=1%High-prevalence threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    99.6%OraQuick sensitivity
    233OFOQ false-negatives
    70%Hands-on time reduction

    Coverage and Medical Necessity Criteria

    Medical Necessity Criteria

    Aetna considers HIV testing medically necessary when ANY of the following conditions are met or when testing follows the CDC/USPSTF algorithm:

    Medical necessity screening indications: 1. Screening per USPSTF and CDC recommendations (routine screening of persons as recommended).

    Refer to USPSTF/CDC guidance for population-specific recommendations.

    Initial laboratory screening test: 2. Initial testing with an FDA-approved antigen/antibody combination immunoassay that detects HIV-1 and HIV-2 antibodies and HIV-1 p24 antigen; no further testing required for specimens nonreactive on the initial immunoassay.

    Use serum or plasma specimens for laboratory immunoassays.

    Reflex differentiation testing: 3. For specimens with a reactive (or repeatedly reactive, per manufacturer/regulatory guidance) antigen/antibody combination immunoassay result, perform an FDA-approved HIV-1/HIV-2 antibody differentiation immunoassay to distinguish HIV-1 from HIV-2 antibodies; interpret concurrent reactive results as positive for HIV-1, HIV-2, or undifferentiated HIV antibodies.

    Laboratories should follow manufacturer and regulatory repeat-testing recommendations as applicable.

    Nucleic acid testing (NAT) after discordant differentiation: 4. If initial antigen/antibody combination immunoassay is reactive and the HIV-1/HIV-2 antibody differentiation immunoassay is nonreactive or indeterminate, perform an FDA-approved HIV-1 nucleic acid test (NAT) with the following interpretive rules: (a) reactive NAT + nonreactive differentiation = laboratory evidence of acute HIV-1 infection; (b) reactive NAT + indeterminate differentiation = HIV-1 infection confirmed by NAT; (c) negative NAT + nonreactive or indeterminate differentiation = false-positive initial immunoassay.

    Follow the CDC-recommended algorithm for sequencing immunoassays and NAT.

    Acceptable alternative point-of-care/oral tests: 5. The Orasure oral HIV test kit (OraSure) and the OraQuick Rapid HIV-1/2 antibody point-of-care test are acceptable alternatives for the same medically necessary indications as standard laboratory HIV testing.

    Specimens submitted to laboratories after a reactive rapid test should be tested beginning with an antigen/antibody combination immunoassay.

    Aetna does not cover home HIV test kits that do not require a physician's prescription under any plans. Examples of non-covered kits include the Confide Home HIV Test (Johnson & Johnson) and the Home Access HIV Test System.

    Studies of the OraQuick oral fluid rapid test (OFOQ) identified a substantial number of false-negative results in longitudinal cohorts. In these analyses there were 233 false-negative OFOQ results among seroconverting participants and delays in oral-fluid conversion with a median of 98.5 days. Because OFOQ failures were frequent and multifactorial, the policy recommends that negative oral fluid rapid test results in longitudinal trials be confirmed by blood testing (e.g., NAAT or enzyme immunoassay).

    Billing and Code Sets

    Covered CPT codesCPTCovered
    86689HTLV or HIV antibody, confirmatory test (e.g., Western Blot)
    86701Qualitative or semiquantitative immunoassay performed by multiple step methods for the detection of antibodies to infectious agents; HIV-1
    86702Qualitative or semiquantitative immunoassay performed by multiple step methods for the detection of antibodies to infectious agents; HIV-2
    86703Antibody; HIV-1 and HIV-2, single result
    87389Infectious agent antigen detection by immunoassay technique (eg, EIA, ELISA, IMCA) qualitative or semiquantitative, multiple-step method; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result
    87390HIV-1
    87391HIV-2
    87534Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, direct probe technique
    87535HIV-1, amplified probe technique, includes reverse transcription when performed
    87536HIV-1, quantification, includes reverse transcription when performed
    1–10 of 11
    1/2
    Covered HCPCS codesHCPCSCovered
    G0432Infectious agent antigen detection by enzyme immunoassay (EIA) technique, qualitative or semi-quantitative, multiple-step method, HIV-1 or HIV-2, screening
    G0433Infectious agent antigen detection by enzyme-linked immunosorbent assay (ELISA) technique, antibody, HIV-1 or HIV-2, screening
    G0435Infectious agent antigen detection by rapid antibody test of oral mucosa transudate, HIV-1 or HIV-2, screening
    G0475HIV antigen/antibody, combination assay, screening
    S3645HIV-1 antibody testing of oral mucosal transudate
    Covered ICD-10 codesICD-10Covered
    B20Human immunodeficiency virus [HIV] disease
    Z11.4Encounter for screening for human immunodeficiency virus [HIV]
    Z20.6Contact with and (suspected) exposure to human immunodeficiency virus [HIV]
    Z20.828Contact with and (suspected) exposure to other viral communicable diseases
    Z21Asymptomatic human immunodeficiency virus [HIV] infection status
    High-prevalence definition
    High-prevalence definitionSettings with 1% or greater prevalence of HIV infection in the patient population served.
    Source guidanceDefinition provided by the Centers for Disease Control and Prevention (CDC) as referenced in policy background.
    Use in screening strategyClinicians should consider local prevalence when determining appropriate screening approaches in high-prevalence settings.

    Provider Actions, Billing Guidance, and Laboratory Algorithm

    Billing Rule

    Billing codes listed — bill with listed codes when criteria met

    CPT, HCPCS, and ICD-10 codes listed in this policy are covered when the clinical and testing-algorithm criteria in the policy are met. Providers should bill using the codes shown in the policy for the corresponding tests.

    • Covered CPT/HCPCS/ICD-10 codes are listed in the policy (see CPT codes such as 86689, 86701-86703, 87389-87391, 87534-87536, 87806; HCPCS codes such as G0432, G0433, G0435, G0475, S3645; ICD-10 codes such as B20, Z11.4, Z20.6, Z20.828, Z21).
    Prior Authorization

    Prior authorization

    No prior authorization requirements are specified in the policy excerpts for these HIV testing services.

    Background and Scope

    HIV testing is indicated for persons with risk factors and for routine screening consistent with USPSTF and CDC recommendations. CDC guidance supports routine, opt-out screening in healthcare settings for most adolescents and adults, and the USPSTF has issued Grade A recommendations for screening in specified age ranges.

    Screening in pregnancy is included in these recommendations; all pregnant women should be screened for HIV as part of routine prenatal care.

    Laboratories and clinicians are advised to follow the CDC-recommended testing algorithm, beginning with an FDA-approved antigen/antibody combination (fourth-generation) immunoassay to improve detection of acute infection, with reflex differentiation immunoassays and nucleic acid testing (NAT) as indicated.

    Definitions and Key Terms

    Opt-out screening
    DefinitionOpt-out screening: routine HIV screening performed after the patient is notified that testing will be performed unless the patient declines.
    CDC-recommended age rangePatients aged 13 to 64 years (CDC recommendation for routine opt-out screening).
    Pregnancy recommendationCDC recommends opt-out screening for pregnant women as part of routine prenatal screening.
    Fourth‑generation HIV test
    DefinitionFourth-generation HIV test: an FDA-approved antigen/antibody combination immunoassay that detects HIV-1 and HIV-2 antibodies and the HIV-1 p24 antigen.
    PurposeImproves detection of acute HIV-1 infection and screens for established HIV-1 or HIV-2 infection; laboratories should begin testing algorithms with an Ag/Ab combination immunoassay.
    Policy Summary
    PayerAetna
    PolicyHIV Testing
    Policy CodePolicy 0542
    Change TypeNo material change
    Effective DateN/A
    Last ReviewAug 4, 2023
    Next Review DateN/A
    Key ActionBegin HIV testing with an FDA-approved antigen/antibody combination immunoassay and follow with differentiation immunoassay and HIV-1 NAT as indicated.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling and Code SetsProvider Actions, Billing Guidance, and Laboratory AlgorithmBackground and ScopeDefinitions and Key Terms
    Note

    Testing algorithm and laboratory actions

    Laboratories and providers must follow the CDC-recommended testing algorithm beginning with an FDA-approved antigen/antibody (Ag/Ab) combination immunoassay for initial screening. Specimens nonreactive on the initial Ag/Ab test require no further testing. Reactive (preliminary positive) initial Ag/Ab results should be followed by an FDA-approved HIV-1/HIV-2 antibody differentiation immunoassay. If the differentiation immunoassay is nonreactive or indeterminate after a reactive initial Ag/Ab result, an FDA-approved HIV-1 nucleic acid test (NAT) should be performed to resolve acute infection versus false positive.

    • Initial test: FDA-approved Ag/Ab combination immunoassay (HIV-1/HIV-2 antibodies and HIV-1 p24 antigen).
    • If initial Ag/Ab is nonreactive: no further testing required.
    • If initial Ag/Ab is reactive: perform FDA-approved HIV-1/HIV-2 antibody differentiation immunoassay.
    • If differentiation immunoassay is nonreactive or indeterminate after reactive initial Ag/Ab: perform an FDA-approved HIV-1 NAT to distinguish acute infection from false-positive results.
    Note

    Algorithm sequencing

    Algorithm sequencing must be followed as specified: start with the Ag/Ab combination immunoassay; follow reactive results with the HIV-1/HIV-2 antibody differentiation immunoassay; if differentiation is nonreactive or indeterminate, perform an HIV-1 NAT. This sequencing determines interpretation (established infection, acute infection, or false-positive initial result).

    Step Therapy

    Step therapy

    No step therapy requirements are described in the provided policy excerpts for HIV testing.

    Documentation Required

    Provider and documentation requirements

    No additional provider-specific requirements or explicit documentation requirements are specified in these chunks beyond following the testing algorithm and using the listed billing codes when criteria are met.

    Denial Risk

    Non-covered home HIV test kits

    Aetna does not cover over-the-counter home HIV test kits that do not require a physician prescription (examples listed in the policy include the Confide Home HIV Test and the Home Access HIV Test System).

    • Non-covered examples: Confide Home HIV Test; Home Access HIV Test System.
    Test examplesLaboratory immunoassays such as the ARCHITECT HIV Ag/Ab Combo and lateral-flow Ag/Ab combo tests (e.g., Determine HIV 1/2 Ag/Ab Combo) are implementations of this approach.
    HIV self‑testing
    DefinitionHIV self-testing (home-based testing): use of an FDA-approved rapid test kit by individuals to perform HIV screening at home, with or without assistance from community health workers.
    FDA-approved exampleOraQuick In-Home HIV Test is the only oral HIV self-test kit currently FDA-approved and available for retail sale (as noted in the policy).
    Potential benefitsMay increase convenience, privacy, and uptake of testing in some populations; research on implementation strategies is ongoing.
    OFOQ false‑negative (oral fluid OraQuick) definition
    DefinitionOFOQ false‑negative: an oral fluid OraQuick rapid test result that is negative for HIV antibodies while contemporaneous NAAT and/or enzyme immunoassay indicate HIV infection (i.e., failure to detect infection).
    Observed frequency and delayIn longitudinal analyses, 233 false‑negative OFOQ results occurred among seroconverting individuals; estimated conversion delay ranged from 14.5 to 547.5 days (median 98.5 days).
    Contributing factorsFalse negatives were associated with test operator/site, pre-exposure prophylaxis, low plasma viral load, and time to kit expiration; age, gender, and HIV subtype were not associated.
    Recommended actionNegative oral fluid results in longitudinal trials should be confirmed by testing blood samples due to frequent and multifactorial failures of oral fluid tests.